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Introduction: Improving public health through providing affordable and accessible phar-
maceuticals is among the concerns of governments worldwide. This study aimed to analyze
Iran’s pharmaceutical sector policies in order to identify the challenges and suggest some
strategic solutions to overcome such challenges.
Methods: Top managers (15), middle managers (10), and operational managers (5) working
in the Food and Drug Administration of Iranian Ministry of Health along with community
pharmacists (5) participated in a qualitative study using semi-structured in-depth interviews.
Data were recorded, transcribed, and then analyzed via MAXQDA 10 software.
Results: Policies for national pharmaceutical sector were divided into four groups of
“research & development”, “import & export”, “pharmaceutical procurement”, and “phar-
maceutical supply and distribution”. Then, the challenges faced by each sector were
extracted. Considering the challenges, some policy options were recommended for growth
and development of national pharmaceutical sector.
Conclusion: Iran’s pharmaceutical sector has managerial and administrative differences
compared with overseas pharmaceutical sectors. These differences are the main reasons for
the current status of Iran’s pharmaceutical sector and have put Iran behind foreign pharma-
ceutical sectors. Iran’s pharmaceutical sector has endured many critical periods during recent
decades and has gained great experience during these stages. Therefore, it is believed that
Iran’s pharmaceutical sector, with its experience and potential, is capable of producing
world-level medicines.
Keywords: pharmaceutical policy-making, research & development, qualitative study,
supportive policy, Iran
Introduction
Pharmaceutical sector policies – as a sub-branch of health sector policies – may
affect the public's access to safe and effective medications and provide some policy
options for health policy-makers.1 High demand for expensive and high tech
medications by both patients and doctors has increased the health sector's expen-
diture during recent years.2 Analyses carried out on Iran’s pharmaceutical market
have revealed some dramatic growth within this sector.3,4 Data suggest that med-
ication costs have raised from $2.28 in 1997 to $34.43 in 2010. Iran’s pharmaceu-
tical sector suffers from issues such as difﬁculties in ﬁnancial exchanges to import
some medications, and low value of Rial in comparison to Dollar which are all due
to sanctions.5 In other words, although there have been no direct sanctions on Iran’s
pharmaceutical sector, since the banks and the system through which the money is
being paid for medications is practically closed on Iran, these sanctions affect the
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pharmaceutical sector indirectly.1,5 On the other hand,
having more than 90 pharmaceutical industries widespread
around the country has reduced economies to scale as well
as their proﬁts.5 Moreover, the existence of some semi-
public pharmaceutical companies has reduced the compe-
tition among pharmaceutical companies. From the produ-
cers’ point of view, pharmaceutical pricing has been the
most challenging issue in recent years. Therefore, the
reference pricing method has been used to meet this chal-
lenge in Iran’s pharmaceutical sector.6,7
Government’s supportive policies for internal production
is one of the other issues around the world. Iranian govern-
ment has also implemented some policies such as creating
tariff and non-tariff barriers or even banning importing of
some medications in order to support national production.8
However, these policies have raised some concerns such as
limiting patients’ choices, the question of whether national
production is more cost-effective or not, and even promoting
the culture of irrational use of medicines.5 Moreover, pub-
lished studies have shown that research and development is
the main weakness of Iran’s pharmaceutical sector.6 R&D is
costly and a long-term strategy. However, most of the phar-
maceutical companies have neither the money nor the time to
invest in this area. Iranian government has also taken some
measures to motivate pharmaceutical companies to advance
their R&D activities.1,5 If the pharmaceutical industry experi-
ences signiﬁcant and considerable growth, then, both essen-
tial and non-essential drugs will be provided for the public
with high quality and proper price. In addition, this will also
affect the people and can improve public health, and we will
have healthier people at work.9–11 Since pharmaceutical
policies and interventions are the most important and effec-
tive policies within the health sector, they must be chosen and
implemented based on logical evidence.1 Countries around
the world have been trying to provide high quality and
effective medicines for their people. Demographic develop-
ments such as ageing, emergence of new medicines, etc.,
have turned pharmaceutical policy-making into a challenging
issue.12,13 Policy makers should apply the most suitable
policy for the pharmaceutical sector so that they can respond
to pharmaceutical needs of the public. Such policies should
also be revised and modiﬁed according to both internal and
external factors.
Iranian Pharmaceutical Sector
Iranian Food and Drug administration, which is a sub-
branch of Iranian Ministry of Health (MOH), is responsi-
ble for the management and regulation of the Iranian
pharmaceutical sector, including biological and herbal
products.3 The national regulatory system of Iran is com-
posed of two main sectors; pharmaceutical affairs and the
national control laboratory.5 The former is responsible for
supervision of manufacturing, distribution, and importa-
tion of medicines. The latter checks the quality, origin, etc.
of the medicines. Registration is the main and the most
important requirement for marketing of medicines in Iran.
First, Iran’s Drug Selection Committee evaluates the new
medicines for inclusion in the Iran Drug list based on their
safety, efﬁcacy, and cost-effectiveness. The registration
process may take up to one year and even longer.
Nonetheless, the process is not always clear and based
on the announced guidelines.14 Iranian Medical Insurance
Council evaluates the medicines included in the Iran Drug
List and if approved, they would be included in the
national health system and reimbursed, up to 90% for
inpatients and 70% for outpatients, by the national insur-
ance scheme.15
With regard to what has been mentioned previously
and considering that medicines play a fundamental role
in maintaining and promoting public health, this study
aimed to analyze Iran’s pharmaceutical sector policies
and develop some practical solutions in order to help it
grow and progress.
Methods
Study Design
In this study, Iran’s pharmaceutical sector policies were
investigated in order to identify the challenges and suggest
some strategic solutions to overcome them. Considering
the topic and the necessity for deep understanding and
explaining of the pharmaceutical sector policies as well
as the ambiguity of pharmaceutical policy-making process,
a qualitative design, using semi-structured in-depth inter-
views, was employed.
An interview guide was developed after performing a
comparative study, reviewing the national pharmaceutical
documents, and using experiences of professional indivi-
duals. The questions of interview guide were reviewed and
modiﬁed by several members of the research team and
then pilot tested with two participants before the start of
the main interviews. The ﬁnal interview guide covered the
following items: content of the pharmaceutical policies
and regulations; approaches for pharmaceutical policy-
making; the effect of the contextual factors on policy-
making process; actors and stakeholders involved in
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policy-making process; and supportive policies for R&D,
procurement, import & export, supply and distribution
sectors (Appendix).
Data Collection And Analysis
Operational, middle, and top managers working in food
and drug administration of Iranian Ministry of Health
along with community pharmacists were recruited at phar-
macies and Ministry of Health in Tehran, capital city of
Iran. Because of the study characteristics and difﬁculty in
access to individuals who agreed to take part in the study,
purposive sampling with maximum variations as well as
snowball sampling were used. Those pharmacists and
managers with at least three years of work experience in
their current position were included in the study. 37 phar-
macists and healthcare managers were invited to take part
in the study; however, two of them declined to participate
due to issues related to their position in the Ministry of
Health. Finally, 35 of them agreed to take part in the study.
All of them gave verbal consent and the ethics committee
of Tehran University of medical sciences granted the ethi-
cal approval (ethics code: 9111119006-1).
The interviews were performed from April to February
2018. 15 participants were top managers, 10 middle man-
agers, and 5 operational managers, and 5 participants were
head pharmacists of community pharmacies.
Using the developed interview guide, the semi-structured
in-depth face-to-face interviews were conducted in Persian
with the participants in their workplaces at a date and time
convenient for them by two trained PhD students of Health
Policy. Two initial pilot interviews were undertaken in order
to improve the interview guide, particularly the interview
questions. Recruitment of participants continued until data
saturation was reached and no extra information, including
new themes/concepts, was revealed.16
The interviews were recorded using a digital recorder
and transcribed by the two interviewers for analysis and
were then analyzed using MAXQDA10 software.
Interviews lasted between 30 to 80 mins.
The qualitative content analysis method described by
Graneheim and Lundman (2004)17 was used to inductively
analyze the data. Content analysis is a method of analyzing
written or verbal data in a systematic way.18 It focuses on
subject and context and highlights variation between the
texts; therefore giving the researchers an opportunity to
analyze manifest and descriptive content as well as latent
and interpretative content.17
First, the interviews were read several times in order to
obtain a sense of the whole. Then, the text was divided
into meaningful units that were summarized, coded, and
organized into groups with similar content as a form of
data categorization. These were then abstracted into sub-
themes. The subthemes were subsequently abstracted into
emerging themes. Three researchers (HS, AS and FE)
discussed and revised the emerging themes. Then, through
a process of reﬂection and discussion, the researchers
agreed on how to sort the data. Finally, the underlying
meaning, which is the hidden concept, of the categories
was assigned a ﬁnal theme.
In addition, clear analysis guidelines were used in
order to limit risks of errors, and to ensure the depend-
ability, transferability, conﬁrmability, and credibility.19
Long and continued involvement with the data through
repeated review and discussion of the interview transcripts
by the research team helped us have a deeper understand-
ing of the data and ensured the credibility of the study.
Independent review of the transcripts by researchers with
diverse clinical and research experience improved the
dependability of the theme identiﬁcation. Contextual data
from the setting were reported to enable reviewers/readers
to evaluate applications to other settings. Figure 1 shows
an example of the data synthesis process from a free text
data sample to code, subthemes and ﬁnal theme.
Results
A total of 35 participants were recruited for the present
study. The mean number of years of work experience of
the participants was 6.8. 75% of them were males and the
rest were females (Table 1).
As pointed out by the participants of this study, there are
four important sections for a pharmaceutical sector. These
sections include R&D, import and export, procurement, and
supply and distribution. Considering these sections, we
Figure 1 An example of the process of development of codes, subthemes, and themes.
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developed a conceptual framework and extracted the themes
and sub-themes accordingly (Table 2).
In the following parts, we are going to discuss the
extracted themes and sub-themes in detail.
Theme One: Research And Development
The rate of investment in R&D is one of the main deter-
minants of a successful pharmaceutical sector. The parti-
cipants stated that there are some challenges for Iranian
pharmaceutical sector with regard to their R&D activities.
These challenges as well as the solutions provided by
interviewees and experts are listed in Table 3.
One of the main issues for the R&D sector is that since
these activities are not strategically disciplined, most of
them are not in accordance with public needs. One of the
informants said,
Your R&D should be in line with your needs. We now
have some researchers who are working on some diseases
which are not the real problem in Iran. It may help the
knowledge but does not help the national pharmaceutical
sector. So, we need to align our research priorities with our
national health polices. (MM8)
Another participant also pointed out, “Each pharmaceuti-
cal company has its own R&D center and they are really
active, however what they do is not in line with social
needs.” (TM12)
Not having enough investment in R&D activities is one
of the other challenges for national pharmaceutical com-
panies. According to one of the informants,
You go and have a look at the ﬁnancial turnover of inter-
national pharmaceutical companies, then you compare
their investment in R&D with our national companies. It
is disappointing when you ﬁnd out how deep this differ-
ence is. (MM 5)
Research and development is a very long process and
requires proper ﬁnancial investment. This may not be
managed by one solo company. Most of the famous com-
panies around the world are multi-national and have share-
holders from various countries. Thus, if we can have a
joint venture between our national companies, it may bring
about some promising results in the long-run. One of the
participants mentioned,
Look, where in the past 35 years have we produced ten
original drugs which we can claim is the results of our
R&D activities. We have not, but some pharmaceutical
companies such as Pﬁzer which is American but has share-
holders from England, Russia, and Japan did. They work
together and have very strong R&D, so they produce some
drugs which can be sold around the world. (TM6)
Pharmaceutical pricing is one of the other effective issues
in R&D. In Iran, this process is under government’s con-
trol, therefore, most of the time R&D costs are neglected
in drug pricing. In recent years, the Iranian government
has tried to solve this issue through establishment of
knowledge-based companies. One of the interviewees said,
Look, we have had problems in R&D, and we still have
and if we continue like this we will always have problems.
A big part of it roots in pharmaceutical pricing. The price
of drugs is not suitable, I mean, companies say that we
Table 1 Socio-Demographic Characteristics Of The Participants (N=35)
Socio-demographic
Characteristics
Number Of Top
Managers
Number Of
Middle Managers
Number Of
Operational
Managers
Number Of
Community
Pharmacists
Total
Number
Gender
Female 2 4 2 1 9
Male 13 6 3 4 26
Age (years)
<30 2 4 2 0 8
30–50 6 5 3 3 17
>50 7 1 0 2 10
Professional experience (years)
3–10 4 5 3 2 14
10–15 7 4 1 2 14
>15 4 1 1 1 7
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cannot do research and produce something with this price.
We need more money to do research. With this price we
can only afford our routine expenditures. (OM4)
Theme Two: Import And Export
The amount of pharmaceutical import and export was one
of the other extracted themes. Although the Iranian gov-
ernment has recently tried to control the import and
improve the export of national production, there are still
some challenges in these areas (Table 4).
The participants expressed that not having proper GMP
conditions is one of the most important challenges for
exporting national production. One of the participants
said, “We don’t have good GMP, and we lose the export-
ing markets to our competitors. We are not good at drug
registration which puts us behind our competitors.” (P3)
Our national exporting trend has weakened during
recent years. Not having strong exporting teams may be
one of the main challenges in this area. According to one
of the informants,
Our companies do not have an exporting strategy, because
they still can easily survive in the national market and do
not need to expand their market internationally. Secondly,
we do not have the necessary knowledge for export
because we lack some exporting specialists. (TM3)
Table 2 The Conceptual Framework Extracted From Interviews And Content Analysis (N=35)
Theme Subtheme Codes
R&D -Pharmaceutical pricing
-GMP conditions
-Market role
- R&D policy making
-Budget allocation
-Supporting knowledge-based
companies
- R&D infrastructure
-Not having proper infrastructure for R&D
-There is no competition between national pharmaceutical companies in
order to make them become innovative
- Aligning research priorities with national pharmaceutical polices
-The establishment of NIMAD center at research deputy of Ministry of Health
- Assessing the pharmaceutical needs in the society
Import and Export -Restrictions on imports
-Important role of government
in balancing import and export
-Restrictions on selling
pharmaceutical raw materials
-High potential for export
among national companies
-Lack of aggregate data for
import policy making
-Appling tariff and non-tariff
barriers for imports
-Necessity of changing insurance policies in order to discipline the imports
-Companies do not have future prospects on pharmaceutical exports
-The role of diplomatic strategies for development of national export
-Lack of familiarity with international rules and laws for pharmaceutical exports
-Having some tax exemptions for importing raw material
Procurement -The important role of pricing -Pharmaceutical pricing is done by Ministry of Health, therefore, sometimes a
suitable price is not determined for a drug and companies have no ﬁnancial
motivation for production
-Most of the attention within drug and food administration is gone for
pharmaceutical procurement
-A list of pharmaceutical shortages is usually available
Supply and Distribution -Establishment of pharmaceutical
portal system
-Having a capillary network in
pharmaceutical distribution
-The issue of drug trafﬁcking
-Drugs are being controlled from production to consumption using certain codes
-Public has access to drugs even at the remotest areas
-Restrictions on supplying some special drugs
Notes: Codes: Interviews were codiﬁed using letter “P” (Pharmacist), “TM” (Top Manager), “MM” (Middle Manager), and “OM”(Operational Manager) followed by an
ordinary number.
Abbreviations: GMP, Good Manufacturing Practice; NIMAD, National Institute for Medical Research Development.
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Choosing appropriate advertising strategies is also one of
the other issues for our national export. For instance,
Turkish pharmaceutical companies owe most of their suc-
cess to their systematic advertisement. However, wrong
methods of advertisements can also ruin the companies’
fame. One of the participants mentioned,
Recently, a few of Iranian companies competed with each
other on wining the Afghanistan pharmaceutical market.
They offered some discounts on their products in such a way
that their drugs price was a lot cheaper than what they were
selling in Iran. This created some doubts on quality of Iranian
drugs, but the problem was their advertising methods. (P2)
Table 3 Challenges Of R&D Sector For National Pharmaceutical Companies (N=35)
Challenges Solutions
Not having a strategic look at R&D sector -Investment in knowledge-based organizations
-Revising the pricing method for pharmaceutical sector
Lack of proper and enough infrastructure for R&D
development
-Creating competition between pharmaceutical companies
-Not having a monopoly in pharmaceutical sector
- Changing the patenting rules
-Creating joint venture between pharmaceutical companies
-Supporting and empowering the national pharmaceutical companies both ﬁnancially
and legally
-Establishment of research institutions
R&D is costly -Reverse engineering of some drugs of which the patent has expired
-Considering R&D and advertisement costs in drug pricing
Table 4 Challenges Of Pharmaceutical Sector In Terms Of Import And Export (N=35)
Challenges Solutions
Lack of proper GMP conditions for pharmaceutical export -Providing facilities for companies and making them match themselves with GMP
guidelines
-Holding some educational courses on export and quality improvement
Inability of national production to compete with foreign drugs -Use of diplomatic relations to overcome barriers for export
-Proper marketing
-Having pharmaceutical specialists at the top level of management of companies
-Using the pharmaceutical market of Persian speaking countries
Selling most of the pharmaceutical raw materials -Development of export market
Increase in the trend of importing high tech and expensive
drugs
-Modifying the insurance system to have these drugs covered
-Making policies in order to prevent from imports parallel with national
production
Increase in the price of ﬁnished product due to old
production lines
-Planning in order to provide raw materials
-Increasing the production up to nominal capacity
-Granting some facilities for pharmaceutical companies
Low quality of national production for export -Development of R&D activities
-Producing some imported drugs within the country
-Weakness in marketing
-Unfamiliarity with registration rules in other countries
-Too much dependence on some traditional markets
-Developing a product marketing strategy
-Planning for and supporting the national companies' advertisements in target
markets
-Mutual negotiation with various countries in order to ease the drug registration
process
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Theme Three: Procurement
International changes and sanctions affect the economic
status of countries. In addition, the pharmaceutical sector
is no exception in this regard. Moreover, provision of
pharmaceutical raw materials has been the most challen-
ging issue for our pharmaceutical sector in recent years.
Table 5 presents the challenges of pharmaceutical procure-
ment along with the suggested solutions to overcome
them.
International sanctions have made the ﬁnancial inter-
actions between companies very difﬁcult; therefore,
Iranian companies are faced with some problems in phar-
maceutical procurement. One of the participants said,
“Sanctions have a tremendous effect on pharmaceutical
market. Your money is blocked in international banks
and you can’t easily buy what you need.” (MM3)
According to our participants, our pharmaceutical pro-
curement sector faces fewer problems and barriers in
comparison to other sectors. One of the participants
pointed out, “If we solve our ﬁnancial problems, I think
we won’t have any serious problem for pharmaceutical
procurement. Of course, our companies also need right
planning to manage their procurement.” (OM2)
Theme Four: Supply And Distribution
The Iranian government has recently put more focus on
supporting the national production. Helping national com-
panies as well as providing facilities for them in order to
have a better selling market have become the top priorities
of Iranian Ministry of Health. Reaching this goal needs
companies to produce high quality drugs. Furthermore,
having a strong distribution system is also an important
tool to achieve such goal. Iranian pharmaceutical distribu-
tion system is challenging with various issues (Table 6).
According to the participants, the excessive number of
corporate units at retail level with no license to work, lack
of tools and new methods for goods' distribution, and lack
of willingness of private and foreign sectors to invest in
modern distribution networks are the most important chal-
lenges for national distribution system. According to one
of the participants,
Right now, one of the issues in distribution is the presence
of many companies which most of them lack the basic
facilities and do not have the necessary requirements to
compete with each other. Therefore, they may try to cir-
cumvent the rules and sell drugs illegally to counties such
as Iraq or Afghanistan. (TM10)
One of the strengths of our distribution system is the
presence of a capillary distribution network. One of the
informants said,
Our distribution network is one of the most successful
networks around the world. Although, it is not as fast as
what we have in Europe, it is really strong and can provide
access to drugs even at the remotest areas of the country.
(MM1)
Discussion
The present study aimed to analyze, for the ﬁrst time, the
Iranian pharmaceutical sector policies in order to identify
the challenges within different sections of this sector so
that proper strategic solutions could be suggested to over-
come these challenges. As pointed out by the participants
in our study, R&D is one of the most important areas in
which international pharmaceutical companies put most of
their investment. Most of the companies around the world
spend almost more than 4% of their income on R&D.5
Table 5 Challenges Of Pharmaceutical Procurement In Iran (N=35)
Challenges Solutions
Improper pricing -Changing the pricing model from cost plus to Reference pricing
-Revising the price of nationally produced drugs
Instability in companies' management
and policy making
Appointing and retaining good managers in pharmaceutical sector
Small production scale of
pharmaceutical companies
-Increasing the production volume through producing some high consumption generic drugs and
exporting them to Asian and African counties
-Producing high quality drugs which can compete at international levels
-Creating joint venture
-Companies should move toward producing generic drugs which are legally permitted, so that they can
increase their selling.
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However, this sector is not the ﬁrst priority for Iranian
pharmaceutical companies.1 The participants expressed
that a reason for this lies in the relative stability of
Iranian pharmaceutical ﬁrms as well as the low competi-
tion between these ﬁrms. Since we do not have strong
competition between Iranian companies to win the market
shares and each of them has its own certain market share,
they feel no need to invest in their R&D department. On
the other hand, the participants in our study stated that
R&D requires a long-term investment, but managerial and
ﬁnancial instability of companies along with not having
suitable legislation to make companies invest in R&D are
the main barriers to achieving this goal. In a study by
Ghaffari et al, they also mentioned that not having a strong
R&D department is the main obstacle for national phar-
maceutical development.20 Analysis of the interviews sug-
gested that creating joint venture among national
pharmaceutical companies can be a proper strategy in
order to reduce R&D costs so that companies would be
ﬁnancially strong enough to improve their R&D activities.
This is one of the widespread methods used by some
countries around the world.21,22 However, there are both
advantages and disadvantages pointed out for this strategy.
Its advantages include having economies to scale, and cost
sharing. Nonetheless, creating market monopoly in the
pharmaceutical sector, removing some small companies
from the market, increased drug prices, and less govern-
mental control of pharmaceutical pricing are among the
disadvantages.5 Results of a study carried out by Guennif
et al also supported ﬁndings of our study.23
One of the concerns of the participants was that private
companies cannot properly invest in R&D activities due to
the high costs of raw materials' production, low marginal
proﬁt for pharmaceutical products, and weak governmen-
tal supporting polices; so, they are a lot far from innova-
tion and creativity within pharmaceutical sector. In
addition, they pointed out that Iranian universities support
research and projects that can result in published articles,
but such support should be provided for those studies
which can bring about a new and innovative product.
Creating a comprehensive recording network for all tests
and research can prevent doing repetitive projects and will
save the research budget as well. This has also been noted
in some other national studies.24,25
Participants in this study indicated that governments’
supporting policies play a paramount role in development
and growth of national pharmaceutical companies. This
has also been pointed out in different studies,26–28 so we
cannot ignore the role of government as the steward and
legislator for the pharmaceutical sector. However, results
of our study showed that government intervention has
created some inefﬁciencies for some parts of the pharma-
ceutical sector. In our perspective, this may be because
Iranian pharmaceutical companies are neither completely
private nor fully governmental but something between
these two. Some Iranian companies are seemingly private,
but in fact they are supported by the government. In other
words, here the government is the main competitor of the
private sector, and this has created a kind of governmental
monopoly. According to Ding et al, governments should
play their monitoring and policy making roles and provide
suitable facilities for companies so that they improve their
GMP conditions and can compete with their competitors.29
The Iranian pharmaceutical sector has always lacked a
proper strategy for exporting their pharmaceutical products.5
As expressed by the participants, unfamiliarity with
Table 6 Challenges Of Iran’s Pharmaceutical Distribution System (N=35)
Challenges Solutions
Drug trafﬁcking -Establishment of a drug information portal to monitor drugs from
production to consumption
-Increasing the quality of nationally produced drugs in order to
compete with foreign drugs
-Familiarity of importing companies with internal pharmaceutical needs
The distribution network is not based on a clear program and therefore it is
very difﬁcult to be controlled
-Redesigning the operational systems and processes
-Training and empowering human resources about modern
technologies
Producing single goods in many factories and not having strong quality
brands
-Creating competition in sales
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international markets is the main reason for this weakness.
Some other studies have also observed this issue.30,31 Joining
World Trade Organization (WTO) will be a suitable solution
for overcoming this barrier. According to Rahimi et al, this
will help companies improve their technical knowledge,
meet international guidelines and standards, enhance their
competing abilities, and, ﬁnally, ﬁnd better exporting mar-
kets for their products.32 On the other hand, joining WTO
will also help Iranian companies increase their imports
through collaboration with foreign companies.
One of the key strengths of our study is the use of a
qualitative approach, allowing participants to explain their
own experiences and opinions individually. This metho-
dology has allowed the description of the main issues in
our setting. As we beneﬁted from a diversity of age,
gender and professional experience of the study partici-
pants in our study, we are conﬁdent in our ﬁndings.
Probably, one limitation of our study could be the una-
vailability of some major potential participants whom we
could not interview due to some political and security issues.
Conclusion
Despite having better potential to become one of the leading
sectors in the region, the Iranian pharmaceutical sector has
failed to achieve this goal for the past years. According to the
results of the present study, having a super-concentrated
planning system for both national and imported pharmaceu-
tical products within the government, applying ineffective
and inﬂexible pricing system which reduces companies’
motivation to be innovative, and presence of some very
strong semi-public companies are the most challenging
issues for this sector. On the other hand, not including
R&D expenditures in pharmaceutical pricing, and not paying
attention to intellectual property rights have motivated
national companies to only think about making their products
domestic or produce the generic forms of available foreign
drugs. However, national production is also heavily depen-
dent on importing raw materials. The result of such depen-
dency showed itself during the recent sanctions through a
dramatic increase in pharmaceutical shortages as well as
imposing a huge amount of costs on the public.
The results of the current study suggest that establish-
ment of rules related to intellectual property rights can
gradually encourage foreign investors to come to Iran,
and this will provide a great opportunity for technology
and knowledge transfer for the Iranian pharmaceutical
sector. Clearly, such policy along with investment in
exporting national products as well as creation of
knowledge-based institutions will improve the status of
the Iranian pharmaceutical sector worldwide.
Abbreviations
WTO, world trade organization; R&D, research and devel-
opment; GMP, good manufacturing practice.
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